SCHEMBL16930824

SCHEMBL16930824

NC(=NC=O)c1ccc(C2CC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ CYP2C9 P11712 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ HDAC8 Q9BY41 2/20 0.39
▸ HDAC6 Q9UBN7 2/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ HDAC3 O15379 1/20 0.38
▸ HDAC11 Q96DB2 1/20 0.38
▸ ESR2 Q92731 4/20 0.36
▸ DGAT1 O75907 2/20 0.35
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ HAO1 Q9UJM8 1/20 0.34
▸ ESR1 P03372 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ PARP10 Q53GL7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16930801 0.73 CYP2D6 (0.48) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL2762400 0.72 CYP2C9 (0.69) MEN1MAPK1KMT2ACYP2C9ALDH1A1
Hydrochloric Acid SCHEMBL28200483 0.71 CYP2C9 (0.67) MEN1MAPK1KMT2ACYP2C9ALDH1A1
SCHEMBL16930780 0.70 GRIN2B (0.51) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL9258155 0.70 CYP2C9 (0.56) KMT2ACYP2C9ALDH1A1LMNAMAPT
SCHEMBL9258145 0.70 CYP2C9 (0.56) KMT2ACYP2C9ALDH1A1LMNAMAPT
SCHEMBL16596025 0.69 CYP2C9 (0.51) MEN1MAPK1KMT2ACYP2C9ALDH1A1
SCHEMBL16930794 0.69 PARP15 (0.46) MEN1KMT2AALDH1A1MAPTPARP10
SCHEMBL2636394 0.69 MEN1 (0.60) MEN1MAPK1KMT2AHDAC8HDAC6
SCHEMBL2636397 0.69 MEN1 (0.60) MEN1MAPK1KMT2AHDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9716235-B2 9,10-bis[2-(p-substituted phenyl)pyrimidin-4-yl] anthracene compounds, methods of preparing the same, organic electroluminescent devices and organic electroluminescent display apparatus BOE TECHNOLOGY GROUP CO., LTD. (CN) 2017-07-25 — — US disclosed
US-20150214487-A1 9,10-Bis[2-(p-substituted phenyl)pyrimidin-4-yl] Anthracene Compounds, Methods of Preparing the Same, Organic Electroluminescent Devices and Organic Electroluminescent Display Apparatus BOE TECHNOLOGY GROUP CO., LTD. (CN) 2015-07-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150214487-A1 9,10-Bis[2-(p-substituted phenyl)pyrimidin-4-yl] Anthracene Compounds, Methods of Preparing the Same, Organic Electroluminescent Devices and Organic Electroluminescent Display Apparatus P2RY10, P2RY4, APRT MEN1 4459/4885MAPK1 2115/4885KMT2A 3341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback